Clinical Trials
27 trialsNCT05064059 2026-05-26
MK-4280A-007
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT05198934 2026-04-27
CodeBreak300
Amgen
Phase 3 Completed
NCT07492173 2026-03-25
Bioequivalence Study of Trifluridine and Tipiracil Hydrochloride Tablets on Fasting and Fed in Humans
Shandong New Time Pharmaceutical Co., LTD
Phase NA Completed
NCT04776148 2026-02-05
MK-7902-017
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT05600309 2025-11-26
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT05839951 2025-11-12
STAR-T
Bayer
Completed
NCT04393298 2025-05-29
A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors
UCB Pharma
Phase 1/2 Completed
NCT02261532 2024-11-14
A Phase I Study of TAS-102 in Solid Tumors
Taiho Pharmaceutical Co., Ltd.
Phase 1 Completed
NCT04737187 2024-09-24
SUNLIGHT
Taiho Oncology, Inc.
Phase 3 Completed
NCT01607957 2024-09-19
RECOURSE
Taiho Oncology, Inc.
Phase 3 Completed
NCT01867866 2024-09-05
Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone
Taiho Oncology, Inc.
Phase 1 Completed
NCT01867879 2024-09-05
Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid Tumors
Taiho Oncology, Inc.
Phase 1 Completed
NCT01874522 2024-09-05
Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI
Taiho Oncology, Inc.
Phase 1 Completed
NCT01916447 2024-09-05
A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.
Taiho Oncology, Inc.
Phase 1 Completed
NCT02031055 2024-09-05
Study of the Mass Balance of Oral FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors
Taiho Oncology, Inc.
Phase 1 Completed
NCT02301104 2024-09-05
A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment
Taiho Oncology, Inc.
Phase 1 Completed
NCT02301117 2024-09-05
A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment
Taiho Oncology, Inc.
Phase 1 Completed
NCT02500043 2024-09-03
Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer
Taiho Oncology, Inc.
Phase 3 Completed
NCT02860546 2024-09-03
A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC
Taiho Oncology, Inc.
Phase 2 Completed
NCT03274882 2024-07-25
Study of Efficacy and Safety of S 95005 (TAS-102) in Patients With Metastatic Colorectal Cancer Who Failed Standard Chemotherapies
Servier
Phase 2 Completed
NCT03810742 2023-11-18
Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors
PharmaEngine
Phase 1 Completed
NCT03616574 2022-09-21
First-in-human Study of CA102N Monotherapy and CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors
Holy Stone Healthcare Co., Ltd
Phase 1 Completed
NCT03974594 2022-04-19
Bioequivalence Study of Trifluridine and Tipiracil Tablets in Colorectal Cancer Patients
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Completed
NCT03799731 2022-04-14
Study for Evaluation of Murlentamab (GM102) Anti-tumoral Activity in Colorectal Cancers
GamaMabs Pharma
Phase 2 Completed
NCT01955837 2020-11-17
TERRA
Taiho Pharmaceutical Co., Ltd.
Phase 3 Completed
NCT03031691 2020-08-11
A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer
Mereo BioPharma
Phase 1 Completed
NCT02613221 2019-07-31
APOLLON
Takeda
Phase 1/2 Completed